We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cutaneous Leishmaniasis Successfully Treated with Simple New Therapy

By LabMedica International staff writers
Posted on 09 Dec 2014
Print article
Image: Cutaneous leishmaniasis facial lesion, prior to initiation of successful treatment with daylight-activated photodynamic therapy (DA-PDT) (Photo courtesy of Enk CD et al. 2014, and the British Journal of Dermatology).
Image: Cutaneous leishmaniasis facial lesion, prior to initiation of successful treatment with daylight-activated photodynamic therapy (DA-PDT) (Photo courtesy of Enk CD et al. 2014, and the British Journal of Dermatology).
A new study has established an initial proof-of-concept that a daylight-activated (DA) form of photodynamic therapy (PDT) constitutes a simple and effective treatment for many cases of cutaneous leishmaniasis (CL). The novel, low-cost method is highly accessible, also for patients in rural and other areas with enough sunlight and lacking the technological infrastructure needed for conventional PDT.

A team of researchers from the Hadassah Medical Center & University Hospital (Jerusalem, Israel) and the Hebrew University Hadassah Medical School (Jerusalem, Israel), led by Claes Enk, MD, PhD, conducted the study with 31 patients that had been diagnosed with CL, with nonulcerated papulonodular lesions located on anatomical regions easily exposable to daylight: 11 patients with Leishmania major and 20 with L. tropica.

The patients were divided into two treatment groups: 14 underwent treatment in the hospital garden under professional supervision and 17 underwent self-administered treatment at home. Lesions were treated, at weekly intervals, by application of a thick layer of 16% methyl-aminolevulinate (MetvixR) and 30 minutes occlusion, followed by exposure to daylight for 2.5 hours. A limited number of control lesions were either treated with cryotherapy (painful, and required multiple liquid-nitrogen applications by healthcare professionals at the hospital) or left untreated. Lesions were monitored using clinical, microbiological, and molecular clearance as outcome measures.

Conventional PDT is time consuming, painful, and expensive, employing an artificial light source requiring healthcare professional use of equipment only available at specialized treatment centers. DA-PDT not only abolishes the need for an artificial light source instrument, but is relatively painless and in this study was also found to enable patients to very effectively self-administer the treatment at home with no professional assistance. The overall cure rate for hospital-based and self-administered DA-PDT was 88.9% (Intention-to-Treat cure rate 77.4%), for the hospital-based treatment group alone 85.7%, and for the self-administered treatment group 92.3%. All the L. major infected patients responded to treatments, whereas 3 of the L. tropica infected patients failed to respond to DA-PDT (L. tropica lesions are known to be generally less benign and more refractory to treatment).

The authors noted that though only a randomized controlled trial can determine the true efficacy of DA-PDT, the present study serves as proof-of concept of a novel self-administered, relatively painless PDT regimen for treatment of CL. Future studies are also needed to optimize the DA-PDT treatment protocol in terms of light doses, treatment frequencies, and penetration of the photosensitizer in larger and in ulcerated lesions. In addition, the use of alternative photosensitizers with better anti-leishmanial activity should be explored, especially for L. tropica infections.

The study, by Enk CD et al., was published in the British Journal of Dermatology, November 1, 2014, online ahead of print.

Related Links:

Hadassah Medical Center & University Hospitals
Hebrew University Hadassah Medical School


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.